Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

1.

Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial.

Nolan T, Roy-Ghanta S, Montellano M, Weckx L, Ulloa-Gutierrez R, Lazcano-Ponce E, Kerdpanich A, Safadi MA, Cruz-Valdez A, Litao S, Lim FS, de Los Santos AM, Weber MA, Tinoco JC, Mezerville MH, Faingezicht I, Kosuwon P, Lopez P, Borja-Tabora C, Li P, Durviaux S, Fries L, Dubin G, Breuer T, Innis BL, Vaughn DW.

J Infect Dis. 2014 Aug 15;210(4):545-57. doi: 10.1093/infdis/jiu173. Epub 2014 Mar 20.

PMID:
24652494
[PubMed - in process]
Free PMC Article
2.

Gender Differences in Predictors of Self-Reported Physical Aggression: Exploring Theoretically Relevant Dimensions among Adolescents from Santiago, Chile.

Fries L, Grogan-Kaylor A, Bares C, Han Y, Delva J.

Int Perspect Psychol. 2013 Oct 1;2(4). doi: 10.1037/a0034533.

PMID:
24392266
[PubMed]
3.

A recombinant viruslike particle influenza A (H7N9) vaccine.

Fries LF, Smith GE, Glenn GM.

N Engl J Med. 2013 Dec 26;369(26):2564-6. doi: 10.1056/NEJMc1313186. Epub 2013 Nov 13. No abstract available.

PMID:
24224560
[PubMed - indexed for MEDLINE]
Free Article
4.

Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.

Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, Kpamegan E, Courbron D, Fries LF 3rd, Glenn GM.

Vaccine. 2013 Sep 13;31(40):4305-13. doi: 10.1016/j.vaccine.2013.07.043. Epub 2013 Jul 26.

PMID:
23891795
[PubMed - indexed for MEDLINE]
Free Article
5.

Fishes of the Taquari-Antas river basin (Patos Lagoon basin), southern Brazil.

Becker FG, De Fries LC, Ferrer J, Bertaco VA, Luz-Agostinho KD, Silva JF, Cardoso AR, Lucena ZM, Lucena CA.

Braz J Biol. 2013 Feb;73(1):79-90.

PMID:
23644791
[PubMed - indexed for MEDLINE]
Free Article
6.

Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months.

Risi G, Frenette L, Langley JM, Li P, Riff D, Sheldon E, Vaughn DW, Fries L.

Vaccine. 2013 Jan 2;31(2):436-7. No abstract available.

PMID:
23387064
[PubMed - indexed for MEDLINE]
7.

The diversity and management of chronic hepatitis B virus infections in the United Kingdom: a wake-up call.

Tedder RS, Rodger AJ, Fries L, Ijaz S, Thursz M, Rosenberg W, Naoumov N, Banatvala J, Williams R, Dusheiko G, Chokshi S, Wong T, Rosenberg G, Moreea S, Bassendine M, Jacobs M, Mills PR, Mutimer D, Ryder SD, Bathgate A, Hussaini H, Dillon JF, Wright M, Bird G, Collier J, Anderson M, Johnson AM; Collaborative UK Study of Chronic Hepatitis B Infection (CUSHI-B) Study Group.

Clin Infect Dis. 2013 Apr;56(7):951-60. doi: 10.1093/cid/cis1013. Epub 2012 Dec 7.

PMID:
23223601
[PubMed - indexed for MEDLINE]
Free Article
8.

Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine.

Glenn GM, Smith G, Fries L, Raghunandan R, Lu H, Zhou B, Thomas DN, Hickman SP, Kpamegan E, Boddapati S, Piedra PA.

Vaccine. 2013 Jan 7;31(3):524-32. doi: 10.1016/j.vaccine.2012.11.009. Epub 2012 Nov 12.

PMID:
23153449
[PubMed - indexed for MEDLINE]
9.

Comparison of the Kato-Katz and Helmintex methods for the diagnosis of schistosomiasis in a low-intensity transmission focus in Bandeirantes, ParanĂ¡, southern Brazil.

Caldeira K, Teixeira CF, Silveira MB, Fries LC, Romanzini J, Bittencourt HR, Graeff-Teixeira C.

Mem Inst Oswaldo Cruz. 2012 Aug;107(5):690-2.

PMID:
22850963
[PubMed - indexed for MEDLINE]
Free Article
10.

Estimates of genetic parameters for visual scores and daily weight gain in Brangus animals.

Queiroz SA, Oliveira JA, Costa GZ, Fries LA.

Animal. 2011 May;5(6):838-43. doi: 10.1017/S1751731110002442.

PMID:
22440022
[PubMed]
11.

Immunogenicity and Safety of 2 Dose Levels of a Thimerosal-Free Trivalent Seasonal Influenza Vaccine in Children Aged 6-35 Months: A Randomized, Controlled Trial.

Langley JM, Vanderkooi OG, Garfield HA, Hebert J, Chandrasekaran V, Jain VK, Fries L.

J Pediatric Infect Dis Soc. 2012 Mar;1(1):55-63.

PMID:
23687572
[PubMed]
Free PMC Article
12.

A randomized, controlled trial in children to assess the immunogenicity and safety of a thimerosal-free trivalent seasonal influenza vaccine.

Domachowske JB, Blatter M, Chandrasekaran V, Liu A, Jain VK, Fries L.

Pediatr Infect Dis J. 2012 Jun;31(6):605-15. doi: 10.1097/INF.0b013e31824e2924.

PMID:
22333695
[PubMed - indexed for MEDLINE]
13.

Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant.

Ferguson M, Risi G, Davis M, Sheldon E, Baron M, Li P, Madariaga M, Fries L, Godeaux O, Vaughn D.

J Infect Dis. 2012 Mar 1;205(5):733-44. doi: 10.1093/infdis/jir641.

PMID:
22315336
[PubMed - indexed for MEDLINE]
Free Article
14.

Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study.

Langley JM, Risi G, Caldwell M, Gilderman L, Berwald B, Fogarty C, Poling T, Riff D, Baron M, Frenette L, Sheldon E, Collins H, Shepard M, Dionne M, Brune D, Ferguson L, Vaughn D, Li P, Fries L.

J Infect Dis. 2011 Jun 15;203(12):1729-38. doi: 10.1093/infdis/jir172.

PMID:
21606531
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 months.

Risi G, Frenette L, Langley JM, Li P, Riff D, Sheldon E, Vaughn DW, Fries L.

Vaccine. 2011 Aug 26;29(37):6408-18. doi: 10.1016/j.vaccine.2011.04.072. Epub 2011 May 7. Erratum in: Vaccine. 2013 Jan 2;31(2):436-7. Dosage error in article text.

PMID:
21554915
[PubMed - indexed for MEDLINE]
16.

Anaphylaxis following H1N1 pandemic vaccines: safety data in perspective.

Tavares F, Delaigle A, Slavin D, Bauchau V, Fries L, Seifert H.

Vaccine. 2011 Aug 26;29(37):6402-7. doi: 10.1016/j.vaccine.2011.04.026. Epub 2011 Apr 27.

PMID:
21527305
[PubMed - indexed for MEDLINE]
17.

Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations.

Burt D, Mallett C, Plante M, Zimmermann J, Torossian K, Fries L.

Expert Rev Vaccines. 2011 Mar;10(3):365-75. doi: 10.1586/erv.10.172. Review.

PMID:
21434804
[PubMed - indexed for MEDLINE]
18.

A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.

Langley JM, Aoki F, Ward BJ, McGeer A, Angel JB, Stiver G, Gorfinkel I, Shu D, White L, Lasko B, Dzongowski P, Papp K, Alexander M, Boivin G, Fries L.

Vaccine. 2011 Feb 24;29(10):1921-8. doi: 10.1016/j.vaccine.2010.12.100. Epub 2011 Jan 8.

PMID:
21219987
[PubMed - indexed for MEDLINE]
19.

Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.

Langley JM, Frenette L, Ferguson L, Riff D, Sheldon E, Risi G, Johnson C, Li P, Kenney R, Innis B, Fries L.

J Infect Dis. 2010 Jun 1;201(11):1644-53. doi: 10.1086/652701.

PMID:
20423222
[PubMed - indexed for MEDLINE]
Free Article
20.

Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons.

Jackson LA, Gaglani MJ, Keyserling HL, Balser J, Bouveret N, Fries L, Treanor JJ.

BMC Infect Dis. 2010 Mar 17;10:71. doi: 10.1186/1471-2334-10-71.

PMID:
20236548
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk